CHECKPOINT THERAPEUTICS INC (CKPT) Stock Price, Quote, News and Overview
NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock - Currency: USD
CKPT Quote, Performance and Key Statistics
3.13
-0.05 (-1.57%)
The current stock price of CKPT is 3.13 USD. In the past month the price increased by 6.1%. In the past year, price increased by 59.69%.
CKPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CKPT
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The firm is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Company Info
CHECKPOINT THERAPEUTICS INC
95 Sawyer Road, Suite 110
Waltham MASSACHUSETTS 10014 US
CEO: James F. Oliviero
Employees: 23
Company Website: https://checkpointtx.com/
Investor Relations: https://ir.checkpointtx.com
Phone: 17816524500
CHECKPOINT THERAPEUTICS INC / CKPT FAQ
What is the stock price of CHECKPOINT THERAPEUTICS INC today?
The current stock price of CKPT is 3.13 USD. The price decreased by -1.57% in the last trading session.
What is the ticker symbol for CHECKPOINT THERAPEUTICS INC stock?
The exchange symbol of CHECKPOINT THERAPEUTICS INC is CKPT and it is listed on the Nasdaq exchange.
On which exchange is CKPT stock listed?
CKPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHECKPOINT THERAPEUTICS INC stock?
9 analysts have analysed CKPT and the average price target is 12.24 USD. This implies a price increase of 291.05% is expected in the next year compared to the current price of 3.13. Check the CHECKPOINT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHECKPOINT THERAPEUTICS INC worth?
CHECKPOINT THERAPEUTICS INC (CKPT) has a market capitalization of 152.84M USD. This makes CKPT a Micro Cap stock.
How many employees does CHECKPOINT THERAPEUTICS INC have?
CHECKPOINT THERAPEUTICS INC (CKPT) currently has 23 employees.
What are the support and resistance levels for CHECKPOINT THERAPEUTICS INC (CKPT) stock?
CHECKPOINT THERAPEUTICS INC (CKPT) has a support level at 2.95 and a resistance level at 3.32. Check the full technical report for a detailed analysis of CKPT support and resistance levels.
Is CHECKPOINT THERAPEUTICS INC (CKPT) expected to grow?
The Revenue of CHECKPOINT THERAPEUTICS INC (CKPT) is expected to decline by -88.93% in the next year. Check the estimates tab for more information on the CKPT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CHECKPOINT THERAPEUTICS INC (CKPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CKPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CKPT, evaluating the profitability, health, valuation and growth aspects
- CHECKPOINT THERAPEUTICS INC (CKPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHECKPOINT THERAPEUTICS INC (CKPT) Sales and EPS estimates to see what analysts future expectations are.
- CHECKPOINT THERAPEUTICS INC (CKPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHECKPOINT THERAPEUTICS INC (CKPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHECKPOINT THERAPEUTICS INC (CKPT) Stock Chart to make your own analysis
- CHECKPOINT THERAPEUTICS INC (CKPT) Latest news and press-releases to stay up to date.
Does CHECKPOINT THERAPEUTICS INC (CKPT) stock pay dividends?
CKPT does not pay a dividend.
When does CHECKPOINT THERAPEUTICS INC (CKPT) report earnings?
CHECKPOINT THERAPEUTICS INC (CKPT) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of CHECKPOINT THERAPEUTICS INC (CKPT)?
CHECKPOINT THERAPEUTICS INC (CKPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
What is the Short Interest ratio of CHECKPOINT THERAPEUTICS INC (CKPT) stock?
The outstanding short interest for CHECKPOINT THERAPEUTICS INC (CKPT) is 23.02% of its float. Check the ownership tab for more information on the CKPT short interest.
CKPT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CKPT. When comparing the yearly performance of all stocks, CKPT is one of the better performing stocks in the market, outperforming 86.72% of all stocks.
CKPT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CKPT. CKPT may be in some trouble as it scores bad on both profitability and health.
CKPT Financial Highlights
Over the last trailing twelve months CKPT reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 59.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -897.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CKPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to CKPT. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 72.13% and a revenue growth -88.93% for CKPT